BiotechBlog http://www.biotechblog.com Commercial, legal, political, and scientific trends in biotechnology Fri, 05 Feb 2016 09:50:46 +0000 en-US hourly 1 Legal and regulatory update http://www.biotechblog.com/2016/02/05/legal-and-regulatory-update-5/ Fri, 05 Feb 2016 09:50:46 +0000 http://www.biotechblog.com/?guid=ca9ae748e8763ae43deac3e968af55b6 Copyright © thinkBiotech

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Legal and regulatory update
Go to paperABSTRACT: The Office of Fair Trading (OFT) has recently found Genzyme Limited guilty of abusing its dominant posi...

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Legal and regulatory update

Go to paper

ABSTRACT: The Office of Fair Trading (OFT) has recently found Genzyme Limited guilty of abusing its dominant position in the market for the supply of drugs for the treatment of Gaucher disease in breach of the 'Chapter II prohibition' of the Competition Act 1998. Genzyme supplies a drug called Cerezyme, which until recently was the only treatment for Gaucher disease, a rare inherited genetic disorder...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Drug Patent Expirations for Feb 4, 2016 http://www.biotechblog.com/2016/02/04/drug-patent-expirations-for-feb-4-2016/ http://www.biotechblog.com/2016/02/04/drug-patent-expirations-for-feb-4-2016/#respond Thu, 04 Feb 2016 15:43:45 +0000 http://www.biotechblog.com/?p=18375 Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. ELOXATIN (oxaliplatin) Sanofi Aventis Us Patent number: 5,716,988 Expiration Date: Feb 7, 2016 For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

ELOXATIN (oxaliplatin)
Sanofi Aventis Us
Patent number: 5,716,988
Expiration Date: Feb 7, 2016


For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
http://www.biotechblog.com/2016/02/04/drug-patent-expirations-for-feb-4-2016/feed/ 0
Drug Patent Expirations for Jan 28, 2016 http://www.biotechblog.com/2016/01/28/drug-patent-expirations-for-jan-28-2016/ http://www.biotechblog.com/2016/01/28/drug-patent-expirations-for-jan-28-2016/#respond Thu, 28 Jan 2016 16:22:46 +0000 http://www.biotechblog.com/?p=18373 Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. NUEDEXTA (dextromethorphan hydrobromide; quinidine sulfate) Avanir Pharms Patent number: RE 38,115 Expiration Date: Jan 26, 2016 UTIBRON (glycopyrrolate ; indacaterol maleate) Novartis Pharms Corp Patent number: 6,521,260 Expiration […]

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

NUEDEXTA (dextromethorphan hydrobromide; quinidine sulfate)
Avanir Pharms
Patent number: RE 38,115
Expiration Date: Jan 26, 2016


UTIBRON (glycopyrrolate ; indacaterol maleate)
Novartis Pharms Corp
Patent number: 6,521,260
Expiration Date: Jan 31, 2016


SEEBRI (glycopyrrolate)
Novartis Pharms Corp
Patent number: 6,521,260
Expiration Date: Jan 31, 2016


For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
http://www.biotechblog.com/2016/01/28/drug-patent-expirations-for-jan-28-2016/feed/ 0
Make in India — nowhere to go but up http://www.biotechblog.com/2016/01/28/made-in-india-nowhere-to-go-but-up/ http://www.biotechblog.com/2016/01/28/made-in-india-nowhere-to-go-but-up/#respond Thu, 28 Jan 2016 15:21:57 +0000 http://www.biotechblog.com/?p=18365 Copyright © thinkBiotech

Make in India recently published an advertorial in the Washington Post proclaiming that “2016 is India’s Growth Year For Pharma.” I don’t doubt that India has growth potential, as it ranks 51st out of 54 nations that I compare in the Scientific American Worldview scorecard. The problem with Make in India’s encouraging proclamation is that […]

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

source: pixabay.com

source: pixabay.com

Make in India recently published an advertorial in the Washington Post proclaiming that “2016 is India’s Growth Year For Pharma.” I don’t doubt that India has growth potential, as it ranks 51st out of 54 nations that I compare in the Scientific American Worldview scorecard.

The problem with Make in India’s encouraging proclamation is that there are serious systemic problems holding India back.

I have previously published my thoughts on the matter in the Journal of Commercial Biotechnology: Building biotechnology in India – Drugs are not the answer.

Further, while Make in India claims that India is the number one exporter of generic drugs by volume, NSF Science and Engineering Indicators show that China’s pharmaceutical value-add was $139 billion in 2014, wheras India’s was $10 billion. Further, China’s value-add is up 50% from 2011, whereas India’s value-add is up less than 5%. So what does it matter if India is the number one exporter by volume, if they can’t generate revenues?

I am not alone in my pessimistic stance. Hyderabad-based Hetero Pharma said that the country has lost nearly $10 billion worth of investment by not respecting IP norms.

Further, consider the sobering sentiment from the World Bank. India ranks behind the West Bank and Gaza in their latest ‘Ease of Doing Business’ ranking.

To close on a positive note, I think it’s clear that India’s pharmaceutical industry has great growth potential. I just hope that the policy makers and stakeholders are playing it long, and don’t think that 2016 will be a substantial inflection point.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
http://www.biotechblog.com/2016/01/28/made-in-india-nowhere-to-go-but-up/feed/ 0
Understanding ‘science and the public’ http://www.biotechblog.com/2016/01/27/understanding-science-and-the-public/ Wed, 27 Jan 2016 06:33:53 +0000 http://www.biotechblog.com/?guid=49df0a52726dce91bc47bde35cca7ab2 Copyright © thinkBiotech

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Understanding 'science and the public'
Go to paperABSTRACT: Public acceptance of the products of biotechnology is an important issue for the industry. T...

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Understanding 'science and the public'

Go to paper

ABSTRACT: Public acceptance of the products of biotechnology is an important issue for the industry. This paper looks at relevant academic and policy developments in the field of public understanding of science, which considers the role of science in the public sphere. It traces the interaction of scientists, social scientists and the public in the move from early 'deficit' conceptions of public understanding to more recent positions in which the public are seen as active participants in a variety of contexts for science...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Festo: The plague continues http://www.biotechblog.com/2016/01/17/festo-the-plague-continues-2/ Sun, 17 Jan 2016 15:35:01 +0000 http://www.biotechblog.com/?guid=21cf42ae535fcd7fe8d0642623f9c54e Copyright © thinkBiotech

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Festo: The plague continues
Go to paperABSTRACT: This paper reviews the law on the doctrine of equivalence and prosecution history estoppel and explores...

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Festo: The plague continues

Go to paper

ABSTRACT: This paper reviews the law on the doctrine of equivalence and prosecution history estoppel and explores how it has been reshaped by the Federal Circuit's and Supreme Court's decisions in Festo Corp. v Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd. The paper also assesses the likely impact those decisions will have on patent prosecution, licensing and enforcement activities.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Drug Patent Expirations for Jan 14, 2016 http://www.biotechblog.com/2016/01/14/drug-patent-expirations-for-jan-14-2016/ http://www.biotechblog.com/2016/01/14/drug-patent-expirations-for-jan-14-2016/#respond Thu, 14 Jan 2016 16:30:40 +0000 http://www.biotechblog.com/?p=18313 Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. ZEMPLAR (paricalcitol) Abbvie Patent number: 5,597,815 Expiration Date: Jan 13, 2016 For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

ZEMPLAR (paricalcitol)
Abbvie
Patent number: 5,597,815
Expiration Date: Jan 13, 2016


For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
http://www.biotechblog.com/2016/01/14/drug-patent-expirations-for-jan-14-2016/feed/ 0
DrugPatentWatch adds expired patents from 1985 to present http://www.biotechblog.com/2016/01/13/drugpatentwatch-adds-expired-patents-from-1985-to-present/ http://www.biotechblog.com/2016/01/13/drugpatentwatch-adds-expired-patents-from-1985-to-present/#respond Wed, 13 Jan 2016 15:49:30 +0000 http://www.biotechblog.com/?p=18310 Copyright © thinkBiotech

DrugPatentWatch now contains the most complete resources for pharmaceutical drug patents, expired and acrive, both in the United States and internationally. The most recent addition is the integration of drug patents dating back to the oldest records held by the US Food and Drug Administration. International equivalents for US patents are also available in more […]

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

drug-patentsDrugPatentWatch now contains the most complete resources for pharmaceutical drug patents, expired and acrive, both in the United States and internationally.

The most recent addition is the integration of drug patents dating back to the oldest records held by the US Food and Drug Administration. International equivalents for US patents are also available in more than 90 other countries.

The DrugPatentWatch database now includes more than 104,000 international patents, dating back to 1985.

For more information, see the DrugPatentWatch homepage at www.DrugPatentWatch.com. Plans and pricing are posted at http://www.drugpatentwatch.com/subscribe.php .

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
http://www.biotechblog.com/2016/01/13/drugpatentwatch-adds-expired-patents-from-1985-to-present/feed/ 0
Startup America: What it includes and opportunities for innovators http://www.biotechblog.com/2016/01/07/startup-america-what-it-includes-and-opportunities-for-innovators/ Fri, 08 Jan 2016 02:05:41 +0000 http://www.biotechblog.com/?guid=3cbba3272679a9c84f11f8962fbac44b Copyright © thinkBiotech

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Startup America: What it includes and opportunities for innovators

Go to paper

ABSTRACT:   

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Startup America: What it includes and opportunities for innovators

Go to paper

ABSTRACT:   

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Drug Patent Expirations for Dec 31, 2015 http://www.biotechblog.com/2015/12/31/drug-patent-expirations-for-dec-31-2015/ http://www.biotechblog.com/2015/12/31/drug-patent-expirations-for-dec-31-2015/#respond Thu, 31 Dec 2015 17:59:44 +0000 http://www.biotechblog.com/?p=18281 Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. LIVALO (pitavastatin calcium) Kowa Co Patent number: 5,854,259 Expiration Date: Dec 29, 2015 For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
Copyright © thinkBiotech

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

LIVALO (pitavastatin calcium)
Kowa Co
Patent number: 5,854,259
Expiration Date: Dec 29, 2015


For more information try a free trial

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

]]>
http://www.biotechblog.com/2015/12/31/drug-patent-expirations-for-dec-31-2015/feed/ 0